# The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

> **NCT01999114** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 328 (actual)

## Conditions studied

- ECG Effects

## Interventions

- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Naltrexone tablet
- **DRUG:** Placebos (for TDS and for naltrexone and for moxifloxacin)
- **DRUG:** Moxifloxacin tablet

## Key facts

- **NCT ID:** NCT01999114
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01999114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01999114, "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01999114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*